MetrioPharm
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bleicherweg 10, Zürich, Zurich, 8002, Sw...Phone Number
+41 445620335Website
www.metriopharm.comRevenue
$7.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About MetrioPharm
MetrioPharm AG is a clinical-stage company focused on developing innovative treatments using first-in-class self-regulating immunomodulators for inflammatory and infectious diseases. Their lead candidate, MP1032, offers a novel approach to anti-inflammatory therapy, aiming to reduce corticosteroid-related side effects while maintaining efficacy. Initially focusing on rare diseases like Duchenne Muscular Dystrophy, MetrioPharm also sees potential for MP1032 in broader indications such as arthritis and multiple sclerosis. The company utilizes evidence from clinical and preclinical studies to support its mission of providing corticosteroid-sparing alternatives in the pharmaceutical market.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MetrioPharm your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when MetrioPharm launches new products
Congratulate Masked Content for being promoted to Masked Content at MetrioPharm
Click to see if MetrioPharm had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if MetrioPharm has recently received funding, and reach out quickly before it becomes old news!
MetrioPharm, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if MetrioPharm is spiking on competitors!
Earning: See what the market has to say on MetrioPharm recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once MetrioPharm has new funding data
Recommended Actions
Reach out to Masked Content who joined MetrioPharm as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
MetrioPharm is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MetrioPharm is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MetrioPharm.
MetrioPharm Tech Stack
A closer look at the technologies used by MetrioPharm
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Hiring Plans
MetrioPharm has more open roles in Investor Relations than it has had at any time in the past 12 months.
Left Company
Executive Move
Left Company
Executive Move
MetrioPharm News & Media
MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy
Zurich, July 29, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). This milestone follows the U.S. FDA's ODD, underscoring MP1032's potential as a first-in-class therapy that could minimize reliance on high-dose corticosteroids, which cause sevDr. Stephan Rietiker elected as new Chairman of the Board of MetrioPharm AG
Zurich, April 23, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the new Board of Directors unanimously elected Dr. Stephan Rietiker as Chairman at its constituent meeting.Four new members elected to the Board of Directors of MetrioPharm AG
Zurich, April 17, 2025 – MetrioPharm AG, a biotech company developing drugs for inflammatory and infectious diseases, announced today that four new members were elected to the Board of Directors at an Extraordinary General Meeting on April 25, 2025. The new members are Dr. Harald Fricke, Dr. Martina Muttke, Dr. Stephan Rietiker and Dr. Jörg Zwicker. The board members Jörg Gruber and Christoph von Moos will be remaining on the board.MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
Zurich, March 13, 2024 – MetrioPharm AG, a clinical stage biotech company developing drugs for inflammatory and infectious diseases, today announced that it has established a Scientific Advisory Board (SAB). The newly appointed members are:
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding MetrioPharm
Sign Up For FreeTo access detailed company insights
MetrioPharm AG is a clinical-stage company focused on developing innovative treatments using first-in-class self-regulating immunomodulators for inflammatory and infectious diseases. Their lead candidate, MP1032, offers a novel approach to anti-inflammatory therapy, aiming to reduce corticosteroid-related side effects while maintaining efficacy. In... Read More
